TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has chronic Genotype 1 Hepatitis C infection~Exclusion Criteria:~* Subject has been previously treated for HCV~* Has Human Immunodeficiency Virus (HIV)~* Has Hepatitis B~* Has a history of clinically significant medical condition that may interfere with the study (e.g., stroke or chronic seizures or major neurological disorder) or is contraindicated for treatment with peg-IFN and Ribavirin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo + Peg-IFN/Ribavirin (Type: PLACEBO_COMPARATOR): Participants took double-blind Placebo + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
- Vaniprevir 300 mg b.i.d. + Peg-IFN/Ribavirin (Type: EXPERIMENTAL): Participants took double-blind Vaniprevir 300 mg twice daily (b.i.d.) + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
- Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin (Type: EXPERIMENTAL): Participants took double-blind Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
- Vaniprevir 600 mg q.d. + Peg-IFN/Ribavirin (Type: EXPERIMENTAL): Participants took double-blind Vaniprevir 600 mg q.d. + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
- Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin (Type: EXPERIMENTAL): Participants took double-blind Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of KW-6356 in Subjects With Early Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject fulfills the UK Parkinson's Disease Society brain bank clinical diagnostic criteria~* Parkinson's disease patients in Stages 1 to 3 on the Modified Hoehn and Yahr Scale~* MDS-UPDRS part III score of ≥ 15~Exclusion Criteria:~* Use of any CYP3A4/5-related drugs within 2 weeks prior to enrollment.~* Use of any of the specified antiparkinsonian drugs and dopamine antagonists during the specified period.~* Treatment with levodopa/DCI at any time in the past for a period of 4 weeks or more.~* Neurosurgical operation for Parkinson's disease (stereotactic surgery, deep brain stimulation or gamma knife), or treatment by transcranial magnetic stimulation (TMS).~* Either of the following criteria consecutively at screening and enrollment;~  * Resting Pulse \> 100 bpm~ * Resting systolic blood pressure \> 140 mmHg, or diastolic blood pressure \> 90 mmHg~* Significant dementia or a Mini-Mental State Examination (MMSE) score of ≤ 23.~* Subject has a history or evidence of suicidal ideation (severity of 4 or 5) or any suicidal behavior based on an assessment with the Columbia-Suicide Severity Rating Scale (C-SSRS) at baseline.~* Anyone otherwise considered unsuitable for the study by the investigator or sub-investigator including those who are unable to communicate or to cooperate with the investigator or sub-investigator.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- KW-6356 Low Dose (Type: EXPERIMENTAL): Oral administration
- KW-6356 High Dose (Type: EXPERIMENTAL): Oral administration
- Placebo (Type: PLACEBO_COMPARATOR): Oral administration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Above 18 years of age;~* Locally advanced (stage IIIB) or metastatic (stage IV) NSCLC, not amenable to curative surgery or radiotherapy~* Confirmed T790M mutation~* Progressed on previous EGFR TKI treatment. Patients may have also received additional lines of treatment~* Received osimertinib treatment in the participating site between May 1st and Oct 31st 2016~Exclusion Criteria:~• Enrolment in studies that prohibit any participation in this observational study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EGFR T790M Patients (Type: None): Patients with locally advanced/metastatic EGFR T790M positive NSCLC progressed on previous EGFR TKI

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatient at least 12 years of age~* Both genders; females of childbearing potential must be willing to use birth control method~* Pre-bronchodilator FEV1 of 40-90% predicted~* Reversibility FEV1 of at least 12% and 200mls~* Current asthma therapy that includes an inhaled corticosteroid for at least 12 weeks prior to first visit~Exclusion Criteria:~* History of life-threatening asthma~* Respiratory infection or oral candidiasis~* Asthma exacerbation within 12 weeks~* Concurrent respiratory disease or other disease that would confound study participation or affect subject safety~* Allergies to study drugs, study drugs' excipients, medications related to study drugs~* Taking another investigational medication or medication prohibited for use during this study

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluticasone Furoate/Vilanterol (Type: EXPERIMENTAL): Fluticasone furoate/vilanterol inhalation powder once daily + Placebo inhalation powder twice daily for 24 weeks
- Fluticasone Furoate (Type: ACTIVE_COMPARATOR): Fluticasone furoate inhalation powder once daily + Placebo inhalation powder twice daily for 24 weeks
- Fluticasone Propionate (Type: ACTIVE_COMPARATOR): Fluticasone propionate inhalation powder twice daily + Placebo inhalation powder once daily for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria Patients between 18 and 80 years old with type 2 diabetes and insufficient glycemic control (HbA1c 7% to 10%) for whom metformin therapy is inappropriate (intolerability or contraindication)~Exclusion criteria Myocardial infarction, stroke or Transient ischaemic attack in last 6 months Treatment with rosiglitazone or pioglitazone, GLP-1 analogues, insulin or anti-obesity drugs in past 3 months Impaired hepatic function Severe renal impairment current treatment with systemic steroids change in dosage of thyroid hormones hereditary galactose intolerance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Linagliptin (Type: EXPERIMENTAL): 52 week treatment
- Placebo (Type: PLACEBO_COMPARATOR): First 18 weeks of treatment
- Glimepiride (Type: ACTIVE_COMPARATOR): Placebo patients switch to glimepiride week19-52

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Capable of complying with the study procedures.~* Able to provide written informed consent~* Male or female aged 18 to 65 years, inclusive.~* Diagnosis of partial onset seizures~* Minimum of three seizures per 28 days~* Receiving treatment with 1-3 AEDs~* Refractory to at least one AED~* No progressive neurological conditions by recent MRI/CT~* Adequate birth control in women of child-bearing potential~Exclusion Criteria:~* Refractory to OXC for reasons of efficacy~* Recent status epilepticus~* Recent non-epileptic seizures~* Current diagnosis of major depression~* Recent suicidal plan or intent or more than one attempt~* Current use of oxcarbazepine, felbamate for \< 18 months, phenytoin with levels \>15mcg/mL or frequent need for rescue benzodiazepines~* Current use of sodium-lowering non-seizure medications.~* Clinically significant hepatic, renal, or cardiovascular function~* History of recent substance abuse~* Females who are pregnant or lactating.~* Hypersensitivity to OXC or related drugs~* Difficulty swallowing study medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo - four identical tablets taken orally once daily
- 2400 mg SPN-804 (Type: ACTIVE_COMPARATOR): 2400mg OXC XR taken orally once daily as four identical tablets
- 1200mg SPN-804 (Type: ACTIVE_COMPARATOR): 1200mg OXC XR taken orally once daily as four identical tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Transition From Alendronate to Romosozumab (AMG 785)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal women, defined as no vaginal bleeding or spotting for ≥ 12 months~* Low bone mineral density at screening \[defined by a bone mineral density (BMD) T-score ≤ -2.0 and ≥ -4.0 at the lumbar spine (L1 to L4; or BMD T-score of evaluable vertebrae), total hip, or femoral neck\]~* Currently taking alendronate (70 mg weekly or equivalent) exclusively for ≥ 1 year with verbal agreement that the subject has taken ≥ 80% of their doses with good tolerance~Exclusion Criteria:~* History of vertebral fracture, or fragility fracture of the wrist, humerus, hip or pelvis after age 50; or recent bone fracture within 6 months prior to screening~* History of metabolic or bone disease such as Paget's disease, rheumatoid arthritis, osteomalacia, osteogenesis imperfecta, osteopetrosis, ankylosing spondylitis, Cushing's disease, hyperprolactinemia, and malabsorption syndrome~* Vitamin D deficiency (defined as 25-OH-VitD levels \< 20 ng/mL)

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Romosozumab 140 mg (Type: EXPERIMENTAL): Participants received romosozumab 140 mg administered subcutaneously once a month for 3 months.
- Romosozumab 210 mg (Type: EXPERIMENTAL): Participants received romosozumab 210 mg administered subcutaneously once a month for 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed metastatic renal cell carcinoma with measurable disease.~* Tumor tissue available and properly stored for lysate preparation.~* Patients must be at least 4 weeks from their last immunotherapy, radiation, surgery or chemotherapy (6 weeks for nitrosureas) and recovered from all ill effects.~* Karnofsky Performance Status ≥60%~* Life expectancy ≥ twelve weeks~* Adequate end organ function:~* Hematological: ANC ≥ 1000cells/μL, platelets ≥ 75,000/μL, hemoglobin ≥ 8.5 g/dl~* Liver: AST \< 2 x ULN (upper limit of normal) unless due to metastases then \< 5 x ULN, serum total bilirubin \< 2 x ULN (except for patients with Gilbert's Syndrome)~* Renal: serum creatinine \< 2.0 x ULN.~* Pulmonary: FEV1 \> 2.0 liters or \> 75% of predicted for height and age.~* Cardiac: No evidence of congestive heart failure, symptoms of coronary artery disease, myocardial infarction less than 6 months prior to entry, or serious cardiac arrhythmias. Patients over 40 or have had previous myocardial infarction greater than 6 months prior to entry will be required to have a negative or low probability cardiac stress test for cardiac ischemia.~* CNS: No history of brain metastases.~* Women should not be lactating and, if of childbearing age, have a negative pregnancy test within two weeks of entry to the study.~* Appropriate Contraception in both sexes~EXCLUSION CRITERIA:~* Patients may have not have been treated previously with IL-2, IFNα or autologous vaccine.~* Concomitant second malignancy except for non-melanoma skin cancer, and non- invasive cancer such as cervical CIS, superficial bladder cancer without local recurrence, breast CIS.~* In patients with a prior history of invasive malignancy, less than five years in complete remission~* Positive serology for HIV, hepatitis B or hepatitis C,~* Significant co-morbid illness such as uncontrolled diabetes or active infection that would preclude treatment on this regimen.~* Use of corticosteroids or other immunosuppression (if patient had been taking steroids, at least 4 weeks must have passed since the last dose).~* History of autoimmune disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vaccine, Aldesleukin-2, Interferon-a (Type: EXPERIMENTAL): All patients will be treated with autologous tumor cell vaccine administered into inguinal lymph nodes via ultrasound guidance in addition to systemic IL-2 and recombinant interferon alfa. Two cycles of induction IL-2/IFNα-2a followed by 3 cycles of maintenance IL-2 + IFNα-2a.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Safety of HAIC With FOLFOX vs Sorafenib for Patients Who Showed TACE-resistant: a Retrospective Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with HCC according to the European Association for the Study of the Liver (EASL) diagnostic criteria~* TACE failure/refractoriness by Liver Cancer Study Group of Japan (LCSGJ) criteria~* Without extrahepatic metastasis~* The following laboratory parameters:~Platelet count ≥ 60,000/μL Hemoglobin ≥ 8.5 g/dL Total bilirubin ≤ 1.5 mg/dL Serum albumin ≥ 35 g/L ASL and AST ≤ 5 x upper limit of normal Serum creatinine ≤ 1.5 x upper limit of normal INR ≤ 1.5 or PT/APTT within normal limits Absolute neutrophil count (ANC) \>1,500/mm3~Exclusion Criteria:~* Known history of HIV~* History of organ allograft~* Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry.~* Serious non-healing wound, ulcer, or bone fracture~* Evidence of bleeding diathesis.~* Any other hemorrhage/bleeding event \> CTCAE Grade 3 within 4 weeks of first dose of study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- HAIC of FOLFOX (Type: EXPERIMENTAL): Retreatment With hepatic arterial infusion chemotherapy of oxaliplatin , fluorouracil, and leucovorin
- Sorafenib (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Low Dosage of rt-PA in the Treatment of Pulmonary Thromboembolism in China

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age between 18 and 75~* symptomatic PE confirmed by: a high probability ventilation-perfusion lung scanning (V/Q scan) or the presence of intraluminal filling defect on spiral computed tomographic pulmonary angiography (CTPA)~* PTE patients with haemodynamic instability, or cardiogenic shock~* anatomic obstruction more than 2 lobes on CTPA, or defect more than 7 segments on V/Q scan combined with evidence of right ventricular dysfunction(RVD) and pulmonary hypertension on echocardiography~* written informed consent~Exclusion Criteria:~* active bleeding or spontaneous intracranial hemorrhage~* major surgery, organ biopsy or recent puncture of a non-compressible vessel less than 10 days~* cerebral arterial thrombosis within 2 months~* gastro-intestinal bleeding within 10 days~* major trauma within the past 15 days~* neurosurgery or ophthalmologic operation with 30 days~* uncontrolled hypertension (systolic blood pressure \> 180 mmHg and/or diastolic blood pressure \> 110 mmHg)~* recent external cardiac resuscitation manoeuvres~* platelet count \< 100 000/mm3 at admission~* pregnancy, puerperium or lactation with 2 weeks~* infectious pericarditis or endocarditis~* severe hepatic and kidney dysfunction~* hemorrhagic retinopathy due to diabetes~* a known bleeding disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): rt-PA 100 mg continuous intravenous infusion for 2 hours
- group 2 (Type: EXPERIMENTAL): rt-PA 50 mg continuous intravenous infusion for 2 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Use of Cannabidiol (CBD) in Pain Reduction and Opioid Use After Shoulder Arthroscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Patients undergoing an arthroscopic shoulder procedure (rotator cuff repair, decompression, labrum repair)~* Patients ages 18-75, inclusive~* Female patients must be currently practicing effective forms of two types of birth control, which are defined as those, alone or in combination, that result in a low failure rate (less than 1% per year) when used consistently and correctly~* Male patients must be using an effective form of contraception~Exclusion Criteria~* Legally incompetent or mentally impaired (e.g., minors, Alzheimer's subjects, dementia, etc.)~* Younger than 18 years of age~* Older than 75 years of age~* Any patient considered a vulnerable subject: pregnant women or fetuses, children, cognitively impaired adults, prisoners~* History of cannabis abuse or dependence~* History of coagulation abnormalities and thromboembolic disease or current abnormal coagulation test values~* History of stroke or acute coronary syndromes within 3 months before surgery~* Abnormal coagulation profile~* Renal failure (serum creatinine \> 250 μmol/L \[2.83 mg/dL\]) or liver cirrhosis~* Patients with a history of hypersensitivity to Percocet~* Patients that have been on pre-operative opioid management for any reason~* Patients meeting the DSM-V for major psychiatric illness, such as bipolar disorder~* Patients diagnosed with major depression, psychosis, or substance abuse disorder~* Patients with current or a history of suicidal ideation~* Breastfeeding females~* Patients with clinically significant illness, including cardiovascular disorders~* Clinically significant lab abnormalities~* Abnormal LFTs~* Patients with major neurological disorders, such as dementia, Parkinson's disease, cognitive impairment, epilepsy, history of traumatic brain/head injury, or seizures~* Patients with moderate (Child-Pugh B) and severe hepatic impairment (Child-Pugh C).~* Patients taking moderate or strong inhibitors of CYP3A4 and CYP2C19 (listed below) concomitantly~* Patients taking strong CYP3A4 and CYP2C19 inducers (listed below) concomitantly~* Patients taking substrates of UTG1A9, UTGB17, CYP2A1, CYP2B6, CYP2C8, CYP2C9 and CYP2C19 (listed below) concomitantly

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 - CBD (Type: EXPERIMENTAL): None
- Cohort 2 - Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete